A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma

NCT02326025 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG: Olaratumab
DRUG: Doxorubicin

Sponsor

Eli Lilly and Company